<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2314">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04329195</url>
  </required_header>
  <id_info>
    <org_study_id>APHP200409</org_study_id>
    <nct_id>NCT04329195</nct_id>
  </id_info>
  <brief_title>ACE Inhibitors or ARBs Discontinuation in Context of SARS-CoV-2 Pandemic</brief_title>
  <acronym>ACORES-2</acronym>
  <official_title>ACE Inhibitors or ARBs Discontinuation for Clinical Outcome Risk Reduction in Patients Hospitalized for the Endemic Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Infection: the Randomized ACORES-2 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Groupe Hospitalier Pitié-Salpêtrière</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since December 2019, a novel coronavirus called SARS-CoV-2 (severe acute respiratory syndrome
      coronavirus 2) has caused an international outbreak of respiratory illness described as
      COVID-19.

      Individuals with a history of cardiovascular disease develop a more severe illness and have
      higher rates of death.

      Because of the potential interaction between RAS blockers and SARS-CoV-2 mechanism of
      infection, there are ongoing scientific discussions on whether they should be stopped or
      continued in patients with COVID-19.

      It is crucial to determine whether RAS blockers should be discontinued or not in patients
      with COVID-19.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 9, 2020</start_date>
  <completion_date type="Anticipated">August 9, 2020</completion_date>
  <primary_completion_date type="Actual">May 9, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to clinical improvement from day 0 to day 28 (improvement of two points on a seven-category ordinal scale, or live discharge from the hospital, whichever comes first)</measure>
    <time_frame>from day 0 to day 28 or hospital discharge</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary safety endpoint: major adverse cardiac events defined as the composite of cardiovascular death, myocardial infarction, stroke or acute heart failure at day 28</measure>
    <time_frame>at day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical status as assessed with the seven-category ordinal scale on days 7, 14 and 28.</measure>
    <time_frame>at days 7, 14 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days alive free of oxygen.</measure>
    <time_frame>from day 0 to day 28 or hospital discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days alive outside hospital until day28</measure>
    <time_frame>at day28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days alive free of intensive-care unit (ICU) admission or mechanical ventilation (invasive or non-invasive) until day28</measure>
    <time_frame>at day28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days alive free of mechanical ventilation (invasive or non-invasive) until day28</measure>
    <time_frame>at day28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days alive free of ICU admission until day28</measure>
    <time_frame>at day28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of all-cause mortality at day 28</measure>
    <time_frame>at day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of cardiovascular death at day 28</measure>
    <time_frame>at day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days alive free of acute kidney injury until hospital discharge</measure>
    <time_frame>at day 28 to hospital discharge</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">554</enrollment>
  <condition>History of Cardiovascular Disease Treated With RAS Blockers and With SARS-CoV-2 Infection</condition>
  <arm_group>
    <arm_group_label>1: discontinuation of RAS blocker therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>discontinuation of RAS blocker therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: continuation of RAS blocker therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>continuation of RAS blocker therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1: discontinuation of RAS blocker therapy</intervention_name>
    <description>discontinuation of RAS blocker therapy</description>
    <arm_group_label>1: discontinuation of RAS blocker therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2: continuation of RAS blocker therapy</intervention_name>
    <description>continuation of RAS blocker therapy</description>
    <arm_group_label>2: continuation of RAS blocker therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years old.

          -  Chronically treated with RAS blockers (ACE inhibitors or ARBs on the last prescription
             prior to admission with a treatment duration ≥ 1 month).

          -  Diagnosis of COVID-19 confirmed by the presence of SARS-CoV-2 on any biological sample
             with any detection method.

          -  Patients hospitalized in a non-intensive care unit.

          -  Pregnancy test at inclusion visit for women of childbearing potential.

          -  Women of childbearing potential must agree to use adequate contraception according to
             recommendations related to contraception and pregnancy testing in clinical trials, by
             Clinical Trial Facilitation Group (CTFG).

        Exclusion Criteria:

          -  Shock requiring vasoactive agents.

          -  Acute respiratory distress syndrome requiring invasive mechanical ventilation.

          -  Circulatory assistance.

          -  History of malignant hypertension according to the definition of the 2018 ESC/ESH
             guidelines on hypertension.

          -  Uncontrolled blood pressure despite the use of five antihypertensive drugs.

          -  History of nephrotic syndrome.

          -  History of hospitalization for hemorrhagic stroke in the past 3 months.

          -  RAS blockers therapy previously stopped &gt; 48h.

          -  No affiliation to the French Health Care System &quot;Sécurité Sociale&quot;.

          -  Inability to obtain informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles MONTALESCOT, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Cardiologie - Pitié Salpêtrière(APHP) / ACTION Study Group / Univ. Paris 6 (UPMC) - INSERM UMRS 1166</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilles MONTALESCOT, MD, PhD</last_name>
    <phone>+33 1 42 16 30 07</phone>
    <email>gilles.montalescot@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mathieu KERNEIS, MD</last_name>
    <phone>+33 1 42 16 30 74</phone>
    <email>mathieu.kerneis@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiologie, Groupe Hospitalier Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles MONTALESCOT, MD, PhD</last_name>
      <phone>+33 1 42 16 30 07</phone>
      <email>gilles.montalescot@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 28, 2020</study_first_submitted>
  <study_first_submitted_qc>March 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2020</study_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Cardiovascular disease</keyword>
  <keyword>RAS blockers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

